$KMPH Tomorrow is the ...H.C. Wainwright 22nd Annual Global Investment Conference. They are the latest to have reiterated KemPharm as a BUY. Granted their paltry one year projection sucks, but no analyst enjoys getting caught with their pants down. SO WHAT HAS HAPPENED SINCE THEIR LAST PRICE TARGET, THAT JUST MAY BRING ABOUT AN UPGRADE AFTER THEIR CONFERENCE: (1) KemPharm Receives Day-74 Letter for KP415 NDA investors.kempharm.com/news... (2) KemPharm Issues Letter to Shareholders investors.kempharm.com/news... (3) KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484 investors.kempharm.com/news... KemPharm Reports Second Quarter 2020 Financial Results investors.kempharm.com/news... KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA investors.kempharm.com/news... KemPharm’s Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies investors.kempharm.com/news...
  • 7
7 Likes